Bio Path Holdings Stock Today

BPTH Stock  USD 1.75  0.06  3.31%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 84

 
High
 
Low
Very High
Bio Path is trading at 1.75 as of the 23rd of July 2024. This is a 3.31 percent decrease since the beginning of the trading day. The stock's open price was 1.81. Bio Path has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Bio Path Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of June 2024 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
4th of March 2008
Category
Healthcare
Classification
Health Care
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 2.08 M outstanding shares of which 145.39 K shares are currently shorted by private and institutional investors with about 0.05 trading days to cover. More on Bio Path Holdings

Moving together with Bio Stock

  0.72TXG 10X Genomics Buyout TrendPairCorr
  0.61VOR Vor BiopharmaPairCorr

Moving against Bio Stock

  0.52PFE Pfizer Inc Earnings Call This WeekPairCorr
  0.46RVMD Revolution MedicinesPairCorr
  0.45EWTX Edgewise TherapeuticsPairCorr
  0.45IKNA Ikena OncologyPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Bio Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00460.0048
Notably Down
Slightly volatile
Total Current LiabilitiesM1.9 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total916.6 K873 K
Sufficiently Up
Pretty Stable
Total Assets3.1 M3.2 M
Notably Down
Slightly volatile
Total Current Assets2.9 MM
Notably Down
Slightly volatile
Debt Levels
Bio Path can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bio Path's financial leverage. It provides some insight into what part of Bio Path's total assets is financed by creditors.
Liquidity
Bio Path Holdings currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Bio Path Holdings has a current ratio of 15.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Bio Path's use of debt, we should always consider it together with its cash and equity.

Change In Working Capital

3.53 Million
Bio Path Holdings (BPTH) is traded on NASDAQ Exchange in USA. It is located in 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401 and employs 10 people. Bio Path is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.77 M. Bio Path Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.08 M outstanding shares of which 145.39 K shares are currently shorted by private and institutional investors with about 0.05 trading days to cover. Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bio Path Probability Of Bankruptcy
Ownership Allocation
Almost 99.0 percent of Bio Path outstanding shares are held by general public with 0.103 (percent) owned by insiders and only 1.15 % by other corporate entities.
Check Bio Ownership Details

Bio Stock Institutional Holders

InstituionRecorded OnShares
Strategic Advocates Llc2024-03-31
0.0
State Street Corporation2024-03-31
0.0
Warberg Asset Management Llc2023-12-31
0.0
Northern Trust Corp2024-03-31
0.0
Millennium Management Llc2023-12-31
0.0
Renaissance Technologies Corp2023-12-31
0.0
Geode Capital Management, Llc2024-03-31
0.0
Jpmorgan Chase & Co2023-12-31
0.0
Crewe Advisors Llc2023-12-31
0.0
Vanguard Group Inc2024-03-31
13.5 K
Blackrock Inc2024-03-31
2.4 K
View Bio Path Diagnostics

Bio Path Historical Income Statement

As of now, Bio Path's Research Development is increasing as compared to previous years. The Bio Path's current Reconciled Depreciation is estimated to increase to about 198.9 K, while Depreciation And Amortization is projected to decrease to under 179.9 K. View More Fundamentals

Bio Stock Against Markets

Bio Path Corporate Management

Michael MBAVP OperationsProfile
Alan MacKenzieConsultantProfile
Thomas WalkerConsultantProfile
MBA AshizawaDevelopment ResearchProfile
Peter MBAChairman, CoFounderProfile
Jeffery MDConsultantProfile
Victoria RacRegulatory ConsultantProfile

Additional Information and Resources on Investing in Bio Stock

When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(25.26)
Return On Assets
(1.38)
Return On Equity
(4.31)
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.